Prospective Evaluation of Molecular Assays for the Diagnosis of Vaginitis.
Molecular tests to diagnose conditions involving disruption of normal microbiota are difficult to optimize. Using Nugent scored Gram stain (NS) as the reference standard, we evaluated the performance of 3 molecular assays for the diagnosis of bacterial vaginosis (BV) and examined the impact of an incremental increase in bacterial targets. The BD Affirm includes a DNA probe for Gardnerella vaginalis, the Hologic transcription mediated amplification (TMA) analyte-specific reagent (ASR) assay adds a second Lactobacillus spp. target, and the recently cleared in vitro diagnostic use (IVD) Aptima BV assay includes a third target (Atopobium vaginae). Diagnosis of vulvovaginal candidiasis (VVC) by Affirm and Candida vaginitis Hologic TMA ASR assay was assessed using microscopy for yeast as the reference standard. From May to December 2018, 111 women with vaginitis symptoms prompting the clinician to order Affirm were enrolled with informed consent for collection of additional specimens. Clinicians accurately predicted BV as the most likely diagnosis for 71% of the 45 patients with BV. Co-infection occurred in 13.5% of patients. For BV, the specificity of the Aptima IVD (86.3%) was higher than Affirm (60.6%, P=0.0002), but sensitivities were not significantly different. For VVC, the sensitivity of the ASR assay (100%) was higher than Affirm (75.9%, P=0.023) and the specificity of the Affirm (98.8%) was higher than the ASR (86.6%, P=0.004).